1,054 results match your criteria: "The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.[Affiliation]"
Differential methylation analysis in neuropathologically confirmed dementia with Lewy bodies.
Commun Biol
January 2024
Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Dementia with Lewy bodies (DLB) is a common form of dementia in the elderly population. We performed genome-wide DNA methylation mapping of cerebellar tissue from pathologically confirmed DLB cases and controls to study the epigenetic profile of this understudied disease. After quality control filtering, 728,197 CpG-sites in 278 cases and 172 controls were available for the analysis.
View Article and Find Full Text PDFProject Confirm: Accelerated Drug Approvals for CML-Response.
Clin Cancer Res
January 2024
Center for Drug Evaluation and Research, FDA, Washington, District of Columbia.
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Lancet Haematol
January 2024
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:
Article Synopsis
- The study investigates the safety and pharmacokinetics of oral decitabine combined with cedazuridine versus intravenous decitabine in patients with myelodysplastic syndromes or chronic myelomonocytic leukaemia.
- It involved a phase 3 multicentre trial with participants randomly assigned to receive either oral or IV treatment in a crossover design, allowing for direct comparison of the two methods.
- The primary goal was to measure and compare total decitabine exposure over a 5-day period for both formulations to determine the effectiveness of the oral treatment option.
CML and the WHO: Why?
J Clin Oncol
March 2024
Knight Cancer Institute, Oregon Health and Science University.
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
J Natl Compr Canc Netw
December 2023
National Comprehensive Cancer Network.
The NCCN Guidelines for Cervical Cancer provide recommendations for all aspects of management for cervical cancer, including the diagnostic workup, staging, pathology, and treatment. The guidelines also include details on histopathologic classification of cervical cancer regarding diagnostic features, molecular profiles, and clinical outcomes. The treatment landscape of advanced cervical cancer is evolving constantly.
View Article and Find Full Text PDFMultiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
December 2023
National Comprehensive Cancer Network.
Article Synopsis
- - The treatment landscape for relapsed/refractory multiple myeloma has expanded significantly with new options like second generation proteasome inhibitors, immunomodulators, monoclonal antibodies, and CAR T cells, among others.
- - Due to the nature of multiple myeloma, many patients will experience multiple relapses and require various combination therapies that consider their specific resistance patterns and individual factors such as age and health conditions.
- - The NCCN Guidelines for multiple myeloma offer a structured approach to help healthcare providers make informed decisions regarding diagnosis, treatment, and monitoring for patients with relapsed/refractory multiple myeloma.
Phytonutrients and outcomes following breast cancer: a systematic review and meta-analysis of observational studies.
JNCI Cancer Spectr
January 2024
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, MD, USA.
Article Synopsis
- Phytonutrient intake, particularly soy isoflavones, may significantly reduce the risk of breast cancer recurrence and mortality, especially in postmenopausal and estrogen receptor-positive survivors, with optimal doses identified between 20 to 60 mg/day.
- A review of 32 studies found that enterolactone levels measured before and shortly after diagnosis are inversely associated with cancer-specific and all-cause mortality.
- Green tea consumption before diagnosis showed a notable 44% reduced risk of recurrence for early-stage breast cancer, while no protective benefits were observed from cruciferous vegetables.
Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition.
Mol Cell
November 2023
Laboratory for Molecular Cell Biology, University College London, London, UK; UCL Cancer Institute, University College London, London, UK. Electronic address:
Tumor growth is driven by continued cellular growth and proliferation. Cyclin-dependent kinase 7's (CDK7) role in activating mitotic CDKs and global gene expression makes it therefore an attractive target for cancer therapies. However, what makes cancer cells particularly sensitive to CDK7 inhibition (CDK7i) remains unclear.
View Article and Find Full Text PDFArticle Synopsis
- Frontline treatments for advanced ovarian cancer have seen little improvement in cure rates over many years.
- The text emphasizes the need for a multidisciplinary strategy to explore new therapeutic options.
- It highlights the importance of understanding minimal residual disease, which is the phase that contributes to recurring and eventually incurable ovarian cancer.
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor.
Biomed Chromatogr
February 2024
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.
EBNA1 is an Epstein Barr virus (EBV) protein expressed in all EBV-associated cancers. EBNA1 plays a critical role in the replication and maintenance of EBV episomes in latently infected cells. VK-2019 was developed as a highly specific inhibitor of EBNA1 DNA binding activity and is currently in phase 1 development as a treatment for EBV-associated carcinomas.
View Article and Find Full Text PDFBasal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
November 2023
National Comprehensive Cancer Network.
Basal cell carcinoma (BCC) is the most common form of skin cancer in the United States. Due to the high frequency, BCC occurrences are not typically recorded, and annual rates of incidence can only be estimated. Current estimated rates are 2 million Americans affected annually, and this continues to rise.
View Article and Find Full Text PDFNCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
J Natl Compr Canc Netw
November 2023
National Comprehensive Cancer Network.
Article Synopsis
- Novel targeted therapies have transformed how we treat relapsed/refractory B-cell lymphomas, including small molecule inhibitors and antibody-drug conjugates.
- BTK inhibitors are becoming increasingly important in managing mantle cell lymphoma, whether in initial treatment or after relapse.
- Anti-CD19 CAR T-cell therapies and bispecific T-cell engagers have emerged as effective options for treating relapsed follicular lymphoma and diffuse large B-cell lymphoma, leading to key updates in the NCCN Guidelines.
Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method.
Heliyon
November 2023
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
A rapid, sensitive, and simple UHPLC-MS/MS method for the determination of the PARP inhibitor talazoparib in mouse plasma was developed and validated using [C,H]-talazoparib as an internal standard (IS). The assay procedure involved extraction of talazoparib and the IS from plasma using a single-step deproteination and separation of the analytes was achieved on an ACQUITY UPLC RP18 HSS T3 column with a mobile phase gradient at a flow rate of 0.4 mL/min in a run time of 5 min.
View Article and Find Full Text PDFDabrafenib plus Trametinib in Pediatric Glioma with V600 Mutations.
N Engl J Med
September 2023
From the Hospital for Sick Children, University of Toronto, Toronto (E.B., U.T.); the Royal Children's Hospital, University of Melbourne, Murdoch Children's Research Institute, Melbourne, VIC, and the Women's and Children's Hospital, South Australia Health and Medical Research Institute, South Australian immunoGENomics Cancer Institute, and the University of Adelaide, Adelaide - all in Australia (J.R.H.); IRCCS Giannina Gaslini Institute, Genoa (M.L.G.), and IRCCS Bambino Gesù Children's Hospital, Catholic University of the Sacred Heart, Rome (F.L.) - both in Italy; Osaka City General Hospital, Osaka, Japan (J.H.); the Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago (A.P.-F.); Institut Curie, SIREDO Oncology Center, Paris Sciences et Lettres Research University, Paris (I.A.); the Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.L.); Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow (L.P.); the Department of Neuropathology and Clinical Cooperation Unit Neuropathology (F.S.) and the Hopp Children's Cancer Center, German Consortium for Translational Cancer Research, and National Center for Tumor Diseases, German Cancer Research Center, Heidelberg University Hospital, Heidelberg, Germany (F.S., O.W.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (K.J.C.); Children's National Hospital, Washington, D.C. (R.J.P.); Novartis Pharma, Basel, Switzerland (L.S., A.B.P.S.); Novartis Pharmaceuticals, East Hanover, NJ (M.R.); and the University College London Great Ormond Street Institute of Child Health, London (D.R.H.).
Background: Detection of the V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and in combination with trametinib) has shown efficacy in recurrent pediatric low-grade glioma with V600 mutations, findings that warrant further evaluation of this combination as first-line therapy.
Methods: In this phase 2 trial, patients with pediatric low-grade glioma with V600 mutations who were scheduled to receive first-line therapy were randomly assigned in a 2:1 ratio to receive dabrafenib plus trametinib or standard chemotherapy (carboplatin plus vincristine).
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.
Blood Adv
December 2023
Division of Hematology, Mayo Clinic, Rochester, MN.
In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV.
View Article and Find Full Text PDFNCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023.
J Natl Compr Canc Netw
September 2023
National Comprehensive Cancer Network.
Article Synopsis
- The NCCN Guidelines offer healthcare providers a standardized approach for screening and diagnosing breast cancer, covering various clinical situations and types of breast lesions.
- The guidelines are created by a diverse panel of experts from different medical fields, ensuring comprehensive insights and recommendations.
- The panel meets yearly to assess new data and feedback, allowing them to update screening recommendations based on the latest findings and discussions.
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
September 2023
National Comprehensive Cancer Network.
Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM). The NCCN Guidelines for PeM provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated PeM.
View Article and Find Full Text PDFThe JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
Future Oncol
February 2024
Departments of Medical Oncology & Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Results from JAVELIN Bladder 100 established avelumab (anti-PD-L1) first-line maintenance as the standard-of-care treatment for patients with advanced urothelial carcinoma (UC) that has not progressed with first-line platinum-based chemotherapy. We describe the design of JAVELIN Bladder Medley (NCT05327530), an ongoing phase II, multicenter, randomized, open-label, parallel-arm, umbrella trial. Overall, 252 patients with advanced UC who are progression-free following first-line platinum-based chemotherapy will be randomized 1:2:2:2 to receive maintenance therapy with avelumab alone (control group) or combined with sacituzumab govitecan (anti-Trop-2/topoisomerase inhibitor conjugate), M6223 (anti-TIGIT) or NKTR-255 (recombinant human IL-15).
View Article and Find Full Text PDFEngineered peptide-drug conjugate provides sustained protection of retinal ganglion cells with topical administration in rats.
J Control Release
October 2023
Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD, USA; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA. Electronic address:
Effective eye drop delivery systems for treating diseases of the posterior segment have yet to be clinically validated. Further, adherence to eye drop regimens is often problematic due to the difficulty and inconvenience of repetitive dosing. Here, we describe a strategy for topically dosing a peptide-drug conjugate to achieve effective and sustained therapeutic sunitinib concentrations to protect retinal ganglion cells (RGCs) in a rat model of optic nerve injury.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on the effectiveness of the combination of dabrafenib and trametinib for treating pediatric high-grade gliomas (pHGG) with the V600 mutation, which is found in 5%-10% of such cases and has limited treatment options.
- It was a phase II trial involving 41 pediatric patients, and results showed a 56% overall response rate (ORR), with a median duration of response of 22.2 months and a median overall survival of 32.8 months.
- The findings indicate that this treatment combination may offer better outcomes compared to traditional chemotherapy, representing a potential targeted therapy for affected children and adolescents with relapsed or refractory V600-mutant HGG.*
Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas.
Neurooncol Adv
July 2023
Clinical Trials Office, University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA.
Background: Procaspase-3 (PC-3) is overexpressed in various tumor types, including gliomas. Targeted PC-3 activation combined with chemotherapy is a novel strategy for treating patients with high-grade gliomas, with promising preclinical activity. This study aimed to define safety and tolerability of procaspase-activating compound-1 (PAC-1) in combination with temozolomide (TMZ) for patients with recurrent high-grade astrocytomas.
View Article and Find Full Text PDFThis selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on considerations for the comprehensive care of AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology addresses additional aspects of caring for AYA patients, including risk factors, screening, diagnosis, and survivorship.
View Article and Find Full Text PDFNCCN Guidelines® Insights: Survivorship, Version 1.2023.
J Natl Compr Canc Netw
August 2023
National Comprehensive Cancer Network.
Article Synopsis
- - The NCCN Guidelines for Survivorship aim to assist healthcare providers in meeting the diverse needs of cancer survivors by offering screening and treatment suggestions for issues stemming from adult-onset cancer and its treatments.
- - They also promote healthy behaviors and provide guidance on immunizations for cancer survivors to enhance their overall well-being.
- - The latest updates focus on addressing sleep disorders, fatigue, and cognitive function among cancer survivors, based on discussions and insights from expert panels.
Tobacco Use and Tobacco Dependence Management.
Clin Chest Med
September 2023
The Tobacco Treatment and Cancer Screening Clinic, Johns Hopkins Health System, Baltimore, MD, USA; Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Tobacco use is a major public health problem and the leading cause of preventable deaths in the United States and worldwide. Tobacco dependence determines tobacco use and is largely due to nicotine addiction. Such dependence is a disease resulting in a strong desire or compulsion to take tobacco, with difficulty in cessation of tobacco, along with persistent use despite overtly harmful consequences.
View Article and Find Full Text PDFA Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma.
Clin Cancer Res
December 2023
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
Purpose: Treatment of wingless (WNT)-activated medulloblastoma (WNT+MB) with surgery, irradiation (XRT), and chemotherapy results in excellent outcomes. We studied the efficacy of therapy de-intensification by omitting XRT entirely in children with WNT+MB.
Patients And Methods: Tumors were molecularly screened to confirm the diagnosis of WNT+MB.